Prior Authorization Approved but Quantity Rejected: Reconcile Before Escalating

The Short Answer: Three Numbers Decide a Quantity Reject

When a prior authorization is approved but the pharmacy claim still rejects for quantity, the reject usually means a claims edit compared the submitted quantity and days' supply with a plan limit, a daily-dose standard, or the units the authorization itself allows, and found a mismatch or a used-up balance. It rarely means the approval has disappeared. The usual responses are NCPDP reject 76, "Plan Limitations Exceeded," and 7X, "Days Supply Exceeds Plan Limitation," although some programs use other codes for the same problem.

Before anyone re-argues medical necessity, reconcile three numbers:

1. The authorized amount. The quantity, unit and days' supply the approval actually covers, together with its effective dates and any cap on total units or dollars.

2. The regimen math. Dose times frequency across the fill window. NYRx's own example: a once-weekly drug is submitted as 4 units per 28 days, not 4 units per 4 days.

3. The submitted claim. Quantity Dispensed (NCPDP field 442-E7) in the payer's metric decimal unit, Days Supply (405-D5), the NDC in Product/Service ID (407-D7), and the Date of Service (401-D1).

Payer guidance puts claim correction first. Michigan Medicaid's instruction for reject 76 is to "check days' supply and metric decimal quantity." NYRx says most rejections can be resolved at the pharmacy, and that quantity-limit rejections call for adjusting how the claim is submitted rather than asking the prescriber for prior authorization. Medi-Cal Rx resolves reject 76 by resubmitting to meet the quantity limit first, and moves to prior authorization only when resubmission is not appropriate.

When the regimen genuinely exceeds the plan's limit, the next step depends on the plan sponsor: a pharmacy help desk override, a post-limit prior authorization, or, in Medicare Part D, an exception backed by the prescriber's supporting statement. None is guaranteed. Medi-Cal Rx offers no point-of-sale override for reject 76, several products on a Caremark-administered state list carry no prior authorization to exceed their limits, and OptumRx's quantity-limit FAQ says a denied request still leaves only the limited quantity covered.

Why an Approved Authorization Still Rejects at the Point of Sale

A pharmacy claim passes through a series of plan edits during adjudication. The prior authorization satisfies one of them, the edit behind reject 75, "Prior Authorization Required." Quantity and days'-supply edits are separate checks. Medi-Cal Rx describes the two common forms: quantity over time, based on dosing guidelines over a rolling period, and maximum daily dose, based on the maximum number of units allowed per day. Its limits draw on FDA-approved or medically accepted maximum daily doses and length of therapy at a given dose.

The reject code tells you which comparison failed. Caremark's payer sheet lists the claim fields each code points to:

The free-text message matters as much as the code. Caremark's manual says a "Plan Limitations Exceeded" reject includes the actual limit, for example "Maximum Days' Supply = 34" or "Quantity Limit = 100," and requires pharmacies to review the claim response in full, including secondary messages that may sit on another screen.

What the Sub-Edits Reveal

Medicaid edit files show how much a single reject code can hide. New Jersey's pharmacy edit disposition file, last loaded October 4, 2026 when reviewed for this article, lists these edits behind NCPDP 76 and its neighbors. Each points to a different fix:

Two lessons follow. First, an in-date approval can still fail on exhausted units (0717) or on an NDC it does not cover (0770). Second, a quantity error can surface under a cost code: Medi-Cal Rx's reject 78 bulletin tells pharmacies to confirm that quantity, billing units and days' supply are correct, and warns that a previously approved PA may not satisfy its cost ceiling limits.

The Reconciliation Worksheet: Authorization Fields Against Claim Fields

The worksheet below lines up what the approval says with what the claim transmitted. Work it from the top and stop at the first mismatch, because a wrong unit or days' supply makes every later comparison meaningless. Take the authorization side from the approval letter or determination notice rather than from notes of a phone call, and take the claim side from the transmitted claim and its full response.

Two conventions cause most unit disagreements. The first is the metric decimal rule: Michigan's manual asks for quantity dispensed "expressed in metric decimal units," so a liquid product is entered in its metric unit, such as milliliters, rather than as a count of cartons, unless the payer sheet specifies another unit. The second is days'-supply arithmetic for products that are not taken once a day. Caremark's manual, for example, tells pharmacies to calculate eye drops at 15 drops per mL unless more specific drops-per-mL or uses-per-package information exists.

Worked Example: One Fill, Three Submissions

The arithmetic is easier to see with numbers. The figures below are illustrative assumptions, not any plan's published limit or any product's labeling: a once-weekly injectable supplied as a carton of four single-dose pens of 0.5 mL each (2 mL per carton), billed in milliliters, with a plan limit of 2 mL per 28 days and an approval for the same amount.

In the unit error, the approval is not the problem: the claim says 4 mL where 2 mL was dispensed. In the frequency error, the quantity is right, but the days' supply tells the processor that a 28-day carton will be used in 4 days. Neither belongs with the prescriber or the plan as a coverage dispute. The worksheet's job is to catch both before anyone files a new request.

Adjudication Workflow: From Reject to Resolution

The flow below summarizes the order of operations. The escalation branches depend on the plan sponsor, and any of them can end with only the limited quantity covered.

flowchart TD
    A["Quantity reject after PA approval"] --> B["Read the full reject message and any stated limit"]
    B --> C{"Do NDC, quantity, unit and days' supply match the prescription and the approval?"}
    C -->|"No"| D["Correct the claim to describe what was prescribed and dispensed, then resubmit"]
    C -->|"Yes"| E{"Does the message state a remaining or maximum quantity?"}
    E -->|"Yes, within plan parameters"| F["Resubmit at or below the stated amount when timing allows"]
    E -->|"No, the regimen exceeds the limit"| G{"Which route does the plan sponsor allow?"}
    G -->|"Help desk override"| H["Request override, resubmit approved quantity and days' supply, document it"]
    G -->|"Post-limit PA"| I["Prescriber requests a larger quantity"]
    G -->|"Medicare Part D"| J["Exception request with prescriber supporting statement"]
    G -->|"No override or PA to exceed"| K["Plan covers up to the limit only"]
    J --> L{"Decision within 72 hours of the supporting statement?"}
    L -->|"Decision issued"| M["Approved: resubmit. Denied: redetermination rights"]
    L -->|"Deadline missed"| N["Plan forwards the request to the IRE within 24 hours"]

Route One: Fix the Claim Before Touching the Authorization

Correcting a claim means making it accurately describe the prescription and the product dispensed. Caremark's manual states that each claim is a representation that the transmitted information is correct and complete, and that pharmacies must not modify quantities or days' supply to bypass plan edits. Within that boundary, the common corrections are:

• Units. Re-express the quantity in the payer's metric decimal unit, in whole packages where the payer requires them. New Jersey keeps separate edits for "service units inconsistent with product packaging" and "metric quantity must reflect whole package," a sign of how often packaging is the real issue. For how package codes sit inside an NDC, see our guide to reading labeler, product and package codes.

• Frequency math. Days' supply must follow the directions. NYRx gives two examples: drugs whose maximum quantity equals a 30-day supply will reject when billed as a 90-day supply, and a once-weekly drug should be submitted as 4 units per 28 days, not 4 units per 4 days. NYRx tells pharmacies to adjust the submission and not to ask the prescriber for PA when they get these rejections.

• Smallest package or single course of therapy. Caremark allows one specific resubmission. If the quantity is the smallest commercially available package or a single course of therapy (its example is 9 vials of Remicade as a 56-day supply) and the claim rejects for plan limits, the pharmacy may resubmit that quantity with the maximum days' supply stated in the reject message. The pharmacy remains responsible for refill intervals based on the actual days' supply.

• The quantity the message states. Where a sponsor runs a managed drug limitation or quantity-versus-time program, Caremark's reject reads "PLAN LIMITS EXCEEDED" with the quantity left, or "MAX QUANTITY" with an amount per number of days. If quantity remains within the look-back period and plan parameters, the pharmacy can resubmit, after the appropriate amount of time has passed, for an amount equal to or less than the stated amount. If the prescribed quantity exceeds plan parameters, Caremark directs the pharmacy to call the Pharmacy Help Desk to verify whether prior authorization is available.

• Reducing to the limit. For NYRx edit 00550, "Maximum Quantity Exceeded," the program asks the pharmacy to confirm the claim was submitted correctly, reduce the quantity to Medicaid limitations, and notify the prescriber about necessary changes to the order. Caremark separately requires prescriber approval, dated and documented, before any change to the prescription itself, including the directions for use.

Medicare Part D has one narrow, standards-based path for shortened fills. NCPDP's Work Group 9 Part D FAQ (version 43.0, August 2026) describes Submission Clarification Code 47, "Shortened Days Supply Fill," and 48, "Fill Subsequent to a Shortened Days Supply Fill." They were created for trial fills and refill synchronization under Part D's prorated cost-sharing rules: if a shortened fill, or the full fill after it, rejects with a plan limitation error, the matching code may be used. The FAQ adds that plans should have controls to identify fraud, waste and abuse involving these codes. They are not a general way to clear a quantity limit.

Route Two: Help-Desk Override, Post-Limit PA, or Part D Exception

If the corrected claim still exceeds the limit because the prescribed regimen needs more, the escalation route belongs to the plan sponsor. Identify which route exists before anyone calls the plan.

Pharmacy Help Desk Override

In Caremark-adjudicated plans, the Pharmacy Help Desk can take a request for a "Plan Limitation Exceeded" override (section 4.03 of the 2026 manual). If the override is approved under the plan sponsor's parameters, the pharmacy must resubmit with the accurate approved quantity and days' supply and document the override details on the prescription hard copy or electronic prescription record. Section 4.08 adds that Caremark has general prior authorization numbers for some plan sponsors, that a help desk representative can say whether the sponsor allows an override, and that the pharmacy must keep documentation substantiating any override applied. Whether an override exists at all is a sponsor setting, not a pharmacy entitlement.

Post-Limit Prior Authorization

Many quantity limits have a prior authorization route above them, and some do not. The Caremark-administered State of Tennessee list, dated January 2025, publishes limits per 30-day and 90-day supply and marks whether prior authorization is available to exceed each one. It says the limits are based on FDA-approved prescribing information, approved medical guidelines and/or average utilization, and that they "affect only the amount of medication that the prescription benefit plan pays for, not whether you can get a greater quantity." Its prior authorization line is for the prescriber's use only. Selected rows from that list:

Note the windows. A column labeled for a 30-day supply can be measured per 21 or per 25 days, so a claim that looks like an ordinary month's supply can still exceed the limit. The OptumRx quantity-limit FAQ describes the same basic structure: when a prescription is written above the limit, prior authorization is needed before the additional quantity is covered.

Medicaid programs can make the limit itself the trigger for clinical review. Pennsylvania's Department of Human Services requires prior authorization when the prescribed quantity, dose per day or duration of therapy exceeds its limits. Its automated approvals apply only when the prescribed quantity does not exceed the quantity limit and the claims system finds paid-claim history showing the clinical guidelines are met. Other requests go to prior authorization reviewers, and on to a physician reviewer when the guidelines are not met. The Department says it responds within 24 hours of receiving all information reasonably necessary to decide.

Medicare Part D Exception

In Part D, a quantity or dose limit is a utilization tool inside the formulary exceptions process. Under 42 CFR 423.578(b), formulary use includes "a dose restriction, including the dosage form, that causes a particular Part D drug not to be covered for the number of doses prescribed." The enrollee, the enrollee's representative, or the prescriber may file. The prescriber's supporting statement must explain the medical necessity; for a dose restriction, that the number of doses available under the restriction has been ineffective, or is likely to be ineffective or to adversely affect the drug's effectiveness or patient compliance. Paragraph (f) adds that the statement does not guarantee a favorable decision. Medicare.gov's beneficiary page describes the same route: the enrollee or prescriber can ask for an exception if a quantity limit is not medically appropriate. If the question is which request type to file, see formulary exception vs. prior authorization.

The decision clocks under 42 CFR 423.568(b) run from specific events. For a standard exceptions request, the plan must notify the enrollee no later than 72 hours after receiving the prescriber's supporting statement. If no supporting statement arrives within 14 calendar days of the request, the plan must decide no later than 72 hours after the end of that 14-day period. Under paragraph (h), a plan that misses its deadline has made an adverse coverage determination and must forward the request to the Independent Review Entity (IRE) within 24 hours of the deadline. Expedited requests follow a separate, shorter timetable that this article does not cover. The regulation links here point to Cornell's Legal Information Institute copy; the official text is published in the eCFR.

When No Override Exists: Hard Limits, Exhausted Authorizations, Denied Requests

Some reconciliations end with the plan paying for less than the prescription. Recognizing that early saves days of calls.

• No point-of-sale override. Medi-Cal Rx's reject 76 bulletin (October 2023) says that if resubmitting to meet the quantity limit is not appropriate, prior authorization is required for coverage, and "Point-of-sale (POS) overrides are not available." Requests go through one of five channels: CoverMyMeds, the Medi-Cal Rx Secured Provider Portal, an NCPDP P4 transaction, fax, or U.S. mail.

• No PA above the limit. On the Tennessee list, Varubi, Trudhesa, dihydroergotamine (Migranal) and the butalbital combinations carry "No" in the PA-available column. For those products in that plan, the published limit is the ceiling.

• Authorization used up. New Jersey's edit 0717, "prior authorized units/dollars exhausted," and its cutback counterpart, AG edit 0776, fire while the approval is still in date. If the dose rose mid-course, the existing approval cannot absorb the increase at the counter; the prescriber needs an amended or new authorization. If a renewal is refused, see the reauthorization denial appeal workflow.

• Cost ceilings. Medi-Cal Rx's September 2023 cost-ceiling bulletin warns that a previously approved PA may not satisfy reject 78 limits and that a new PA request may be required.

• Denied quantity requests. The OptumRx quantity-limit FAQ, a 2016 plan document hosted by an employer, says that if the request is denied, the plan still covers up to the quantity limit and the member is responsible for the full cost of any amount above it.

• Approved other than as requested. Pennsylvania gives the beneficiary appeal rights when a request is denied or approved other than as requested: 30 days from the notice, with continued coverage of a drug the beneficiary was already receiving if the appeal is hand-delivered or postmarked within 10 days of the notice.

Documentation, Audit Trail, and Compliance Boundaries

The Caremark manual is direct about the compliance line. Pharmacies must not take any step to circumvent plan design or claim edits, must not modify fields such as quantity or days' supply to bypass edits, and must not use an SCC value, prior authorization number, eligibility clarification code or other data element to inappropriately override a reject. Its claims-submission chapter states that violations are subject to audit chargeback, non-compliance charges and possible termination, and that a paid claim is not evidence of compliance.

For any override that is granted, Caremark requires the details to be documented on the prescription hard copy or electronic record, and its audit document list includes documentation substantiating any SCC or override code transmitted. A record that will hold up later typically captures:

• the date of the help desk contact and any reference or representative identifier provided;

• the approved quantity and days' supply, exactly as resubmitted;

• the reject code and message that prompted the request;

• any prescriber approval for a change to the prescription, dated as the manual requires.

Short-term supplies have their own limits. NYRx lets a pharmacist who cannot reach the prescriber, when the medication requires immediate attention, obtain a PA for up to a 72-hour emergency supply of a drug that requires prior authorization, and Medi-Cal Rx allows a 14-day emergency supply in emergency situations. Caremark's manual says that, unless instructed otherwise, pharmacies may not enter emergency-fill overrides without contacting the Pharmacy Help Desk. In Part D, Caremark's transition-fill rules extend to quantity or daily-dose limits that are not safety related, up to an approved month's supply for eligible enrollees, and exclude products dispensed outside safe utilization recommendations. When a Part D prescription cannot be filled at the point of sale, the pharmacy must give the enrollee the CMS-10147 notice, "Medicare Prescription Drug Coverage and Your Rights," which the manual ties to reject 569.

What Access and Hub Teams Should Standardize

Most avoidable quantity rejects come from information that existed at intake but never reached the claim. Five practices close that gap:

1. Record the approval in claim terms. Capture the approved product or NDC, quantity, unit, days' supply, effective and end dates, and any unit or dollar cap, not just "approved" and an expiration date.

2. Agree unit conventions with the dispensing pharmacy. Metric decimal quantity, whole-package rules and drop-count conventions for ophthalmics should be settled before the first fill, not after the first reject.

3. Keep an escalation map by sponsor. The table below summarizes the named programs in this article; each row is a dated example, not a rule for other plans.

4. Track consumption against authorized units. For titrating or dose-escalating regimens, compare cumulative dispensed units with the approval and start the amended request before the cap is reached. Set the lead time from each payer's actual turnaround. For lapses tied to dates rather than units, see preparing the reauthorization record.

5. Re-check the sources on a schedule. The 2026 Caremark manual supersedes all prior versions; the Tennessee list cited here is dated January 2025; the NCPDP FAQ is at version 43.0; NYRx revised its rejection guide on September 10, 2026; and Medicare.gov notes that from January 1, 2027, plans may be able to process prior authorization requests electronically. For the data side of that change, see electronic prior authorization readiness for specialty drugs.

None of this changes the coverage decision itself. It makes sure the plan is asked the right question: whether a claim that describes the real prescription can be paid, and if it cannot, which sponsor-defined route remains.

Sources

• 2026 Caremark Provider Manual — CVS Caremark. Claim submission policies (section 4.02), the Plan Limitations Exceeded reject and help desk override (4.03), general prior authorization numbers and override documentation (4.08), managed drug limitation and quantity-versus-time messaging (5.07), audit documentation, and Part D transition fill.

• Reject Codes Provider Manual Appendix B (Caremark payer sheet) — CVS Caremark, dated 12/01/2022. NCPDP reject codes 64, 75, 76, 7X and 9G and the claim fields each is tied to.

• State of Tennessee Prior Authorization, Step Therapy and Quantity Limit List (Caremark-administered) — January 2025. Quantity limits per 30-day and 90-day supply, the PA-available-to-exceed column, and zero initial limits.

• NYRx Pharmacy Rejections: How to Identify and Resolve (rev. 09/10/26) — New York Medicaid pharmacy program. Quantity-limit resolution, the weekly-dosing example, edit 00550, and the 72-hour emergency supply.

• How to Resolve Reject Code 76: Plan Limitations Exceeded — Medi-Cal Rx, California DHCS, October 2, 2023. Quantity-over-time and maximum-daily-dose limits, resubmission first, and no point-of-sale override.

• Pharmacy Edit Disposition File by NCPDP Code (NJMMIS) — New Jersey Medicaid. Edit numbers behind NCPDP codes 76, E7, 64 and AG; last loaded October 4, 2026 when reviewed.

• D.0 Pharmacy Claims Processing Manual (Michigan Medicaid) — Michigan MDHHS and Prime Therapeutics, version 1.66, May 6, 2026. Metric decimal quantity entry and the reject 76 disposition.

• NCPDP WG9 Medicare Part D FAQ, Version 43.0 (August 2026) — National Council for Prescription Drug Programs, Work Group 9. Submission Clarification Codes 47 and 48 for shortened days' supply fills.

• 42 C.F.R. § 423.578: Exceptions for enrollees requesting non-formulary drugs or drugs without restrictions — Cornell Legal Information Institute copy of the eCFR text. Dose restrictions within the exceptions process and the prescriber supporting statement.

• 42 C.F.R. § 423.568: Timeframes for coverage determinations — Cornell Legal Information Institute copy of the eCFR text. The 72-hour and 14-calendar-day clocks and IRE forwarding after a missed deadline.

• Medicare.gov: Part D plan rules (drug list, prior authorization, step therapy, quantity limits) — Centers for Medicare & Medicaid Services. Quantity limits, exception requests, transition fills, and the January 1, 2027 electronic prior authorization note.

• OptumRx Quantity Limit Program Frequently Asked Questions — OptumRx, 2016 plan document hosted by an employer. Prior authorization above the limit and coverage up to the limit after a denial.

• How to Resolve Claim Reject Code 78: Cost Exceeds Maximum — Medi-Cal Rx, California DHCS, September 8, 2023. Cost ceilings that a previously approved PA may not satisfy, and the 14-day emergency supply.

• Pharmacy Prior Authorization General Requirements — Pennsylvania Department of Human Services. PA triggers for quantity, dose and duration limits, automated approvals, review timing, and appeal rights.